The double burden of malnutrition: How undernutrition and obesity became one problem

How undernutrition and obesity coexist in the same countries, households and people. The double burden of malnutrition defined, with WHO and Lancet data.

Key takeaways

  • The double burden of malnutrition means undernutrition and overweight, obesity, or diet-related noncommunicable diseases coexist in the same population, household, or person.
  • It has grown fastest in the poorest countries, driven by rapid food-system change, cheap ultra-processed foods and drinks, and reduced physical activity.
  • In 2024, 150.2 million children under five were stunted, 42.8 million wasted, and 35.5 million overweight.
  • One person can experience both: examples include stunting with overweight in a child, or overweight with anemia or micronutrient deficiency.

The Millennium Development Goals carried a hunger target: halve the proportion of people suffering from hunger between 1990 and 2015. While the world narrowly missed that target, what the hunger indicator failed to identify concurrently was the prevalence of obesity, especially in some of the world’s poorest communities.

The State of Food Security and Nutrition in the World 2026 reports on both trends. An estimated 645 million people faced hunger in 2025. In the same report, adult obesity prevalence rose from 12.1% in 2012 to 16.2% in 2024. FAO, IFAD, UNICEF, WFP and WHO publish both figures together, because they now describe one problem.

The double burden of malnutrition is the term for that combination: undernutrition and overweight in the same population, the same household, and sometimes the same person.

This page explains that double burden, its causes, and its mechanism inside one body, as well as what GLP-1 weight-loss medicines change about it.

Scope: this page describes population-level data, indicator definitions, and policy. It is educational and is not medical advice.

What the double burden of malnutrition means

WHO defines the double burden of malnutrition as the coexistence of undernutrition along with overweight, obesity, or diet-related noncommunicable diseases and states that it can occur at all levels of the population: country, city, community, household, and individual (WHO policy brief, 2017).

Undernutrition here is broader than hunger. The WHO malnutrition fact sheet, updated 1 March 2024, includes wasting (low weight-for-height), stunting (low height-for-age), underweight (low weight-for-age), and micronutrient deficiency as types of undernutrition. (Some sources separate micronutrient deficiency from undernutrition and identify it as a third form along with underweight and obesity and call the result the triple burden.)

LevelOverlapsHow it is measured
Population or countryHigh undernutrition prevalence alongside high overweight prevalence in the same national surveyWHO cut-offs of 20% or more stunting together with 10% or more child overweight
HouseholdOne undernourished member and one overweight member in the same householdCommonest measured pairing: a stunted child with an overweight or obese mother
IndividualTwo forms of malnutrition in one personStunting with overweight in the same child, or overweight with anemia or micronutrient deficiency in the same person

The national cut-offs in that table come from Lerm et al., Public Health Nutrition, 2021, which applied them across 93 countries. Two papers can report very different double burden prevalence for the same country by using different levels or different pairings. Record the level and the cut-off before comparing any two figures.

The nutrition transition and what drives it

The double burden has grown fastest in the poorest countries, and almost all of that growth comes from overweight and obesity.

The nutrition transition describes a shift in diet and physical activity patterns that accompanies urbanization, rising income, and food system change, moving a population’s dominant nutrition problem from insufficient energy toward excess energy and diet-related chronic disease. Popkin, Corvalan, and Grummer-Strawn set out the current account in The Lancet, 2020, volume 395, pages 65 to 74, published online in December 2019. They attribute the rise to rapid food system change, including cheap ultra-processed food and drink, as well as to large reductions in physical activity at work, in transport, at home, and in leisure.

Regional prices vary greatly between low-income and high-income countries. Headey and Alderman converted prices for 657 standardized food products from the 2011 International Comparison Program into caloric prices across 176 countries (The Journal of Nutrition, 2019, volume 149, issue 11, pages 2020 to 2033).

Most non-cereal foods were relatively cheap in high-income countries, including sugar-rich and fat-rich ones. In lower-income countries, healthy foods were generally expensive, especially animal-sourced foods and fortified infant cereals. A one standard deviation increase in milk prices was associated with a 2.8 percentage point increase in stunting prevalence. A one standard deviation increase in soft drink prices was associated with a fall in overweight prevalence of about 3.6 percentage points.

The average cost of a healthy diet rose to 4.28 purchasing power parity dollars per person per day, up from 2.94 in 2017 (SOFI 2026). By 2025, 2.69 billion people, or 32.7% of the world, could not afford a healthy diet. One price structure moves both indicators, and that is the shortest answer to how one country produces both outcomes.

Tirzepatide for weight loss and the double burden

The double burden describes undernutrition and obesity in the same country or household, and sometimes the same person. For much of the period this site documents, obesity policy focused on prevention, and tirzepatide (Mounjaro, Zepbound) adds a treatment option. Availability depends on diagnosis and health-system capacity, and on price.

Tirzepatide is a GIP and GLP-1 receptor agonist. Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight with at least one weight-related comorbid condition.

SURMOUNT-1 was a 72-week phase 3 trial of 2,539 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) and at least one weight-related complication, excluding diabetes. Mean percentage change in weight at week 72 was -15.0% with 5 mg, -19.5% with 10 mg, and -20.9% with 15 mg weekly tirzepatide. The placebo group had -3.1%.

SURMOUNT-5 included 751 adults with obesity but without type 2 diabetes for 72 weeks. At the maximum tolerated dose, least-squares mean percent change in weight at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide. These results show tirzepatide for weight loss can be effective for eligible patients. They do not show it treats undernutrition. They do not show it treats food insecurity or the food environment.

Why this complicates the double burden rather than resolving it

Countries with the heaviest combined burden may also face the greatest difficulty paying for treatment. WHO says high prices are limiting access, and it also cites inadequate health-system preparedness and potential equity implications.

  • WHO counted 2.5 billion overweight adults in 2022, including 890 million living with obesity.
  • Self-pay Zepbound prices checked in October 2026 started at $299 a month for the 2.5-mg starting dose and $449 a month for 7.5 mg, 10 mg, 12.5 mg, or 15 mg when refilled within 45 days.
  • A health system funding undernutrition programs may now face another pharmaceutical budget line for obesity and related conditions.
  • Neither tirzepatide nor another weight-loss medicine addresses the nutrition transition behind the problem. Treatment and prevention still compete for resources.

For treatment cost measured against an income line, see the poverty gap ratio.

Where the double burden shows up: country, household, child

The double burden applies at both macro and micro levels of the population. How it is addressed depends on which level the double burden is observed at any given time.

Start at the population level, where the figures are largest and interpretation is easiest. The WHO malnutrition fact sheet reports that in 2022, 2.5 billion adults were overweight, of whom 890 million had obesity, while 390 million adults were underweight. The UNICEF, WHO, and World Bank Joint Child Malnutrition Estimates report that in 2024, 150.2 million children under age five were stunted (23.2%), 42.8 million were wasted (6.6%), and 35.5 million were overweight. Popkin and colleagues identify Indonesia as the largest country with a severe double burden, and many other Asian and sub-Saharan African countries are in the same position.

The monitoring framework already treats these as one measurement. SDG indicator 2.2.2 is a single indicator reporting wasting and overweight as two types, and both read off the same weight-for-height distribution against the WHO Child Growth Standards. Below minus two standard deviations is wasting. Above plus two is overweight. The indicator set built to track hunger now counts child overweight in the same line.

At the individual level, the evidence is narrower. Lerm, Crochemore-Silva, Costa, and Victora studied 825,633 children under five in nationally representative surveys from 93 low- and middle-income countries since 2005 (Public Health Nutrition, 2021, volume 24, pages 2944 to 2951). Using the WHO national cut-offs, they observed a national double burden in five countries where chance alone would predict eleven. At individual level, 30 of the 93 countries (32.3%) showed more concurrent stunting and overweight than chance would predict, though most differences were small.

While coexistence at country level is expected, excess co-occurrence in the same child, in a third of the countries studied, is not.

Why early undernutrition raises later metabolic risk

Malnutrition research is split into undernutrition on one side and overweight on the other, and the nutrition transition puts a rising share of individuals through both within one life course. Wells, Sawaya, Wibaek, Mwangome, Poullas, Yajnik, and Demaio set out the biology in The Lancet, 2020, volume 395, pages 75 to 88.

Their account runs on two quantities. Early-life undernutrition depletes metabolic capacity for homoeostasis, the body’s room to absorb an energy load without dysregulation. Later exposure to a high-energy diet then imposes a metabolic load on that reduced capacity, and the mismatch raises the risk of noncommunicable disease. That dysregulation is measured by the cluster of measurements behind metabolic syndrome.

The biological pathways they name are imbalance of the gut microbiome, inflammation, metabolic dysregulation, and impaired insulin signaling. The same pathways underlie how fatty liver develops. In women, they report, the same trajectory raises the risk of childbirth complications.

Timing is specific. Winichagoon and Margetts, writing in Energy Balance and Obesity (IARC Working Group Reports No. 10, 2017), describe undernutrition during pregnancy and in the first two years of life as a major determinant of stunting risk and of later disease vulnerability. Early undernutrition followed by rapid weight gain was associated with elevated obesity and noncommunicable disease risk in adulthood.

Read that way, the coexistence stops being a paradox. It is one exposure sequence, measured at two points in a life.

Why programs designed for undernutrition can raise overweight risk

Nutrition policy inherited the same split the research had. Hawkes, Ruel, Salm, Sinclair, and Branca open their contribution to the series by noting that actions on different forms of malnutrition are typically managed by separate communities, policies, programs, governance structures, and funding streams (The Lancet, 2020, volume 395, pages 142 to 155).

The consequence is documented rather than hypothetical. Their paper reports that some evidence shows programs focused on undernutrition have raised risks of poor-quality diets, obesity, and diet-related noncommunicable diseases, especially in countries going through a rapid nutrition transition, and it documents examples of such unintended harm.

WHO’s 2017 companion policy brief defines double-duty actions as interventions, programs, and policies that can simultaneously reduce the risk or burden of both undernutrition and overweight, obesity, or diet-related noncommunicable diseases.

It sets out three routes:

  • Do no harm, by checking that existing undernutrition actions do not raise overweight or noncommunicable disease risk.
  • Retrofit, by modifying existing nutrition actions to address other forms of malnutrition.
  • Build new integrated actions aimed at the double burden from the start.

Hawkes and colleagues identify 10 such actions. SDG 2 covers hunger and nutrition and SDG target 3.4 addresses noncommunicable disease mortality, which is why the double burden appears under both.

What the double burden of malnutrition does not measure

A double burden figure is a coexistence statement built from anthropometric cut-offs. It is not a causal finding.

  • It does not establish cause. Two conditions occurring in one unit of analysis is not evidence that one produced the other. At country level, Lerm et al. found fewer countries meeting the WHO thresholds than chance alone would predict.
  • It is not comparable across definitions. A figure computed from a stunted child with an overweight mother is a different quantity from one computed from stunting and overweight in the same child.
  • It says little about diet quality. The IARC chapter (2017) notes that global nutrition data typically capture only weight and height, with limited dietary pattern, body composition, and biochemical data from low- and middle-income countries, and few longitudinal studies.
  • Adult categories carry the usual BMI caveats. Check age standardization and whether the underlying data were measured or self-reported.

Before quoting a double burden figure, record four things: the level, the cut-off, the survey, and the reference year.

FAQ

What is the double burden of malnutrition?

WHO defines the double burden of malnutrition as the coexistence of undernutrition along with overweight, obesity or diet-related noncommunicable diseases (WHO policy brief, 2017). It can occur at country, city, community, household, and individual level. Undernutrition here covers wasting, stunting and micronutrient deficiency, so it is broader than insufficient food energy.

How can food insecurity and obesity exist in the same country?

Food insecurity and obesity can exist in the same country because access to dietary energy and access to dietary quality are not the same thing. The State of Food Security and Nutrition in the World 2026 reports that 645 million people faced hunger in 2025, while 2.69 billion could not afford a healthy diet that year. Adult obesity prevalence rose from 12.1% in 2012 to 16.2% in 2024.

Can one person be undernourished and overweight at the same time?

Yes. The pairings most often measured are stunting with overweight in the same child, and overweight with anemia or micronutrient deficiency in the same person. Across 93 low- and middle-income countries, Lerm et al. (2021) found more concurrent stunting and overweight than chance would predict in 30 of them.

What is the difference between the double burden and the triple burden of malnutrition?

The triple burden lists micronutrient deficiency as a separate third form alongside undernutrition and overweight. WHO’s double burden definition already places micronutrient deficiency within undernutrition, so the terms overlap. Check which definition a source uses before comparing figures.

Is tirzepatide on the WHO Essential Medicines List?

Yes, tirzepatide is on the WHO Essential Medicines List. In September 2025, WHO added tirzepatide to the Model List of Essential Medicines, along with semaglutide, dulaglutide, and liraglutide, for adults with type 2 diabetes who have established cardiovascular disease, chronic kidney disease, and who also have obesity.

Does tirzepatide for weight loss reach low- and middle-income countries?

High prices limit access, WHO says, and it also cites inadequate health-system preparedness. WHO’s December 2025 guideline conditionally recommended GLP-1 therapies for long-term obesity treatment in adults, excluding pregnant women, and it cites cost and equity barriers. The guideline says medication alone will not solve obesity. See non-communicable diseases and SDG target 3.4.

Sources

developmentgoals.org documents these statistics and cites the agencies that produce them. It does not produce them.